Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis

Figure 5 Combination analysis of the survival data. Overall survival (A) and disease-free survival (B) in hepatocellular carcinoma patients based on NG2 expression and TNM stage. a: TNM stages I/IIwith NG2 low expression; b: TNM stages I/IIwith NG2 high expression; c: TNM stages III/IV with NG2 low expression; d: TNM stages III/IV with NG2 high expression; Overall survival (C) and disease-free survival (D) in hepatocellular carcinoma patients based on NG2 expression and serum AFP. a: Low level of serum AFP with NG2 low expression; b: Low level of serum AFP with NG2 high expression; c: High level of serum AFP with NG2 low expression; d: High level of serum AFP with NG2 high expression; Overall survival (E) and disease-free survival (F) in hepatocellular carcinoma patients based on NG2 expression and venous invasion. a: No invasion with NG2 low expression; b: No invasion with NG2 high expression; c: Invasion with NG2 low expression; d: No invasion with NG2 high expression.